Otter Health bets that prior authorization can be replaced, not accelerated
Prior authorization has become one of healthcare’s most entrenched sources of conflict, and the next fight is no longer limited to faxed forms and manual review queues. As payers deploy algorithmic claims tools and large language models to speed appeals, Otter Health is pushing a different premise: the system should reduce the need for authorization in the first place by steering care toward evidence-based decisions in real time.
The startup has emerged with $8 million in seed funding, co-led by Fika Ventures and Evidenced Capital, with backing from Slow Ventures, Metrodora, CoFound Partners, Patient Capital, SemperVirens and Layout Ventures. Its platform is built around a simple but ambitious idea: if clinicians and payers can see the same clinical evidence at the point of decision, the review process can shift from obstruction to guidance.
That is a sharp break from the traditional utilization management model.
Real-time clinical review instead of retrospective friction
Otter Health’s platform compares clinical decisions against evidence-based standards across referrals, outpatient procedures and care transitions. The company says its software creates a shared view for payers and providers, identifies variation and prompts clinician engagement before an episode of care becomes a dispute. Rather than wait for claims to be filed or a prior authorization request to be denied, the system is designed to intervene while decisions are still being made.
The underlying logic is clinically familiar. Many unnecessary services persist not because clinicians lack intent, but because fragmented workflows and payer rules create incentives that pull decision-making in different directions. By placing evidence at the center of the workflow, the platform aims to reduce low-value care while preserving clinician judgment for cases where deviation from standard pathways is justified.
Otter’s founders have spent years in utilization management, clinical quality and healthcare technology. The team includes healthcare strategy leaders and clinicians Amol Navathe, M.D., Ph.D., Keith Florance, Ram Keralapura and Will Bartlett. Florance, who has worked at Evolent Health and Boston Consulting Group and later led payer business at Clarify Health Solutions, argued that the industry has mistaken faster prior authorization for a real solution.
Speeding up the paperwork does not change the nature of the paperwork.
Why the company says the workflow itself is the problem
Florance described a marketplace in which providers try to secure as much care as possible for patients while payers respond by adding barriers to payment. Otter’s thesis is that both sides are trapped in a system that rewards defensiveness rather than shared clinical accountability. The company is trying to replace that adversarial loop with a transparent quality framework that can be used across routine decisions, not just the subset that triggers a formal prior auth checkpoint.
The platform automatically analyzes each physician decision against what Otter describes as gold-standard evidence. When a decision does not align with the standard of care, the physician receives a notification and a rationale; missing documentation can also be flagged. The point is not simply to generate more alerts, but to give clinicians an immediate clinical explanation and to reserve intervention for decisions that are meaningfully outside accepted practice.
That approach depends on trust. Florance said the company wants to engage providers only when there is a strong reason to do so, because constant low-value alerts would quickly erode credibility. In that sense, the product is less like a control panel and more like a clinical guide that can surface variation without forcing every decision through a bureaucratic checkpoint.
Early deployments point to a narrower authorization footprint
Otter says organizations using its platform have been able to remove prior authorization in certain areas while keeping non-concordant clinical decisions below 5%. The company also says those organizations captured substantial savings on low-value care that would otherwise have moved outside the authorization process.
Those early figures matter because a great deal of waste sits beyond the reach of traditional prior authorization. Otter estimates that roughly 60% of low-value healthcare spending occurs outside those controls, which means a system focused only on preapproval can still miss a large share of unnecessary care. In practical terms, a health plan can tighten one doorway and still allow excess utilization through a dozen others.
By extending decision-level analysis to referrals, outpatient procedures, pathway adherence and care transitions, Otter is trying to move the center of gravity from gatekeeping to continuous measurement. The company says that model can help payers manage networks with more clinical precision while giving providers a clearer sense of how their decisions compare with evidence-based practice.
The payer-provider relationship sits at the center of the pitch
Bryan Sivak, managing partner at Evidenced and former chief technology officer at the U.S. Department of Health and Human Services, framed the opportunity in straightforward terms: payers need confidence that they are paying for appropriate care, and physicians need room to exercise judgment without repeatedly defending every decision through paperwork. The process linking those needs has become expensive and adversarial.
Otter’s bet is that credible evidence, delivered in real time and paired with clinician engagement, can create enough accountability to make prior authorization the exception rather than the default. The company argues that the shift could also help reduce the administrative burden that has made prior authorization a flashpoint in almost every discussion about access, cost and physician burnout.
The broader policy environment may give that pitch some momentum. Federal rules and state laws are already pushing health plans to drop prior authorization for routine services, but plans still want visibility into care quality. That leaves a gap for tools that can monitor appropriateness without recreating the old friction under a different name.
What the funding is meant to buy
The seed round is intended to expand Otter’s platform into additional specialties, build out engineering and physician teams, and widen adoption across health plans, health systems and risk-bearing provider groups. The company says it is already working with major payers and provider organizations.
The commercial case is layered. Health plans can reduce administrative expense and unnecessary utilization. Providers can get clearer feedback on standard-of-care alignment. And if the platform truly works at scale, both sides may be able to replace some prior auth workflows with an ongoing quality framework that measures care at the decision point rather than after the fact.
Kate Goodrich, executive in residence at Optum and a former Humana chief medical officer and CMS Center for Clinical Standards and Quality director, said that greater visibility into evidence-based practice can support clinicians while improving cost control and access. Her view reflects the core tension in utilization management: the system needs guardrails, but it also needs a way to avoid turning every deviation into a paperwork battle.
Otter is entering a market crowded with tools designed to automate prior auth and claims review, but it is arguing for something more structural. The open question is whether payers and providers will accept real-time clinical quality measurement as a substitute for the long-standing gatekeeping model, or whether they will keep adding faster technology to a workflow that both sides already distrust.